XERS Share Price Performance
US$7.61
4.20 (123.17%)
33.8% undervalued intrinsic discount
US$11.50
Fair Value
Price US$7.61
AnalystConsensusTarget US$11.50
AnalystHighTarget US$17.23
AnalystLowTarget US$8.00
Fair ValueUS$11.50
Share Pricen/a
Xeris Biopharma Holdings, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 17 Fair Values set on narratives written by author
XERS Community Narratives
AN
Fair Value US$11.5 33.8% undervalued intrinsic discount
XERS: Higher 2025 Revenue Guidance Will Drive Measured Financial Outlook
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
Fair Value US$17.23 55.8% undervalued intrinsic discount
Rising Global Chronic Illness Will Drive Self-Administered Endocrine Therapies Expansion
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$8 4.9% undervalued intrinsic discount
Rising Healthcare Costs And Regulation Will Erode Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Rising Healthcare Costs And Regulation Will Erode Margins
Key Takeaways Dependence on a limited product lineup exposes Xeris to revenue risks from shifting demand, reimbursement pressures, and increased competition. Rising regulatory barriers, coupled with growing R&D and commercial expenses, threaten to prolong losses and undermine future profitability.Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$8
4.9% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
20.38% p.a.
Profit Margin
16.19%
Future PE
26.43x
Price in 2029
US$10.77
Rising Global Chronic Illness Will Drive Self-Administered Endocrine Therapies Expansion
Key Takeaways Xeris is positioned for rapid earnings growth and margin expansion due to strong product adoption, innovative pipeline, and operational discipline in underserved endocrine markets. Structural healthcare trends and new commercial channels could unlock substantial long-term revenue streams and support accelerated market share gains.Read more
18
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$17.23
55.8% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
29.85% p.a.
Profit Margin
30.99%
Future PE
23.7x
Price in 2028
US$21.05
XERS: Higher 2025 Revenue Guidance Will Drive Measured Financial Outlook
Key Takeaways Strong demand for key therapies and strategic investments in commercialization and partnerships are expected to drive sustained revenue growth and operational leverage. Expansion into underserved markets and focus on innovation position the company to capture new revenue streams and support long-term profit margin improvement.Read more
253
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
US$11.5
33.8% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
21.81% p.a.
Profit Margin
20.21%
Future PE
29.38x
Price in 2028
US$14.05
Trending Discussion
Recently Updated Narratives
AN
XERS: Expanding Hypercortisolism Market And Q3 Delivery Support Measured Cash Outlook
Fair Value: US$8 4.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
XERS: Expanding Hypercortisolism Market Will Drive Stronger Long Term Cash Generation
Fair Value: US$17.23 55.8% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
XERS: Expanding Hypercortisolism Market Presence Will Drive Future Cash Generation
Fair Value: US$11.5 33.8% undervalued intrinsic discount
8 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Xeris Biopharma Holdings, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Mar 02, 2026
- -0.094
- 84.56%
- -5.88%
- -25,490.0%
About XERS
- Founded
- 2005
- Employees
- 394
- CEO
- WebsiteView website
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
